The Florey: New target in MND drug discovery Posted in Impact by The Florey Institute of Neuroscience and Mental Health on August 3rd, 2022. New research from the Florey Institute of Neuroscience and Mental Health investigates how a previously underappreciated type of cell in the brain and spinal cord, known as oligodendrocytes, potentially contributes to the progressive loss of motor neurons in Motor Neurone Disease (MND). This is a major step towards new drug discovery for the currently incurable disease affecting an estimated 400,000 people. Find out more about the research and its findings here. Disclaimer: This material has been prepared by The Florey Institute of Neuroscience and Mental Health, published on 3 August 2022. HM1 is not responsible for the content of linked websites or content prepared by third party. The inclusion of these links and third-party content does not in any way imply any form of endorsement by HM1 of the products or services provided by persons or organisations who are responsible for the linked websites and third-party content. This information is for general information only and does not consider the objectives, financial situation or needs of any person. Before making an investment decision, you should read the relevant disclosure document (if appropriate) and seek professional advice to determine whether the investment and information is suitable for you.